InnotiveDx

InnotiveDx is a Liverpool-based medical diagnostics company developing a revolutionary point-of-care system for diagnosing urinary tract infections. Spun out of the University of Liverpool in 2021, the company was founded to solve a persistent and costly problem in primary care: UTIs affect hundreds of millions of people worldwide each year and account for more than 20% of all antibiotic prescriptions, yet the standard diagnostic method — laboratory plate culture — takes 48 to 72 hours to return results. This forces clinicians to prescribe antibiotics empirically, contributing significantly to antimicrobial resistance.

InnotiveDx's platform identifies the causative pathogen and its antibiotic sensitivities in under 60 minutes at the point of care — a setting where no comparable solution currently exists. The fully automated system has demonstrated over 96% agreement in blinded evaluations against one of the world's largest diagnostic companies, and has received overwhelmingly positive feedback from clinical usability studies conducted with end-users in the United States. By enabling targeted antibiotic prescribing at the time of consultation, InnotiveDx has the potential to significantly reduce treatment failure rates and slow the spread of antimicrobial resistance.

InnotiveDx has raised over £3 million through a combination of Innovate UK grants and equity investment, and has been highlighted in Nature as a high-impact innovator. The company has grown to more than 20 employees and is now progressing toward large-scale clinical studies ahead of regulatory submission and commercial launch in the UK and internationally.